Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Attribution Theory00:56

Attribution Theory

12.9K
Behavior is a product of both the situation (e.g., cultural influences, social roles, and the presence of bystanders) and of the person (e.g., personality characteristics). Subfields of psychology tend to focus on one influence or behavior over others. Situationism is the view that our behavior and actions are determined by our immediate environment and surroundings. In contrast, dispositionism holds that our behavior is determined by internal factors (Heider, 1958).
12.9K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.8K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

8.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.4K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

335
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
335
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

2.7K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the socioeconomic value of adult respiratory immunization in Spain: a benefit-cost analysis.

Expert review of vaccines·2026
Same author

Evaluating the societal value of adult respiratory vaccination in Sweden: a benefit-cost analysis.

Expert review of vaccines·2026
Same author

Readiness to Consider and Adopt Genetic and Genomic Tests in Canada-An Update to the State of Readiness Report.

Current oncology (Toronto, Ont.)·2026
Same author

Applying Health Economics and Outcomes Research Methods in Value-Based Healthcare Implementation: An ISPOR Special Task Force Report.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

A cost-benefit analysis of adult immunization programs across ten countries: Modeling the socioeconomic value of immunization for older populations compared to no vaccination.

Human vaccines & immunotherapeutics·2025
Same author

Two-Stage Estimation of Overall Survival in the Phase 3 CheckMate 9ER Trial, Adjusting for the Impact of Subsequent Therapy.

Oncology and therapy·2025
Same journal

Are preference-weighted cancer-specific measures more sensitive than generic measures? A comparison of EQ-5D-5L, SF-6Dv2, FACT-8D and QLU-C10D in gastrointestinal cancers.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2025

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

15.1K

Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies.

Lotte Steuten1, Mickael Lothgren2, Andrew Bruce3

  • 1Office of Health Economics, London, England, UK.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|August 10, 2024
PubMed
Summary
This summary is machine-generated.

A new value attribution solution prices combination therapy components based on relative value, addressing competition law and pricing challenges. This universal and symmetrical approach offers a complete valuation framework for complex drug combinations.

Keywords:
combination treatmentshealth policyhealth technology assessmentoncologyvalue attribution

More Related Videos

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.1K
Pavlovian Conditioned Approach Training in Rats
06:57

Pavlovian Conditioned Approach Training in Rats

Published on: February 4, 2016

10.9K

Related Experiment Videos

Last Updated: Jun 17, 2025

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making
11:51

Combining Behavioral Endocrinology and Experimental Economics: Testosterone and Social Decision Making

Published on: March 2, 2011

15.1K
Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

12.1K
Pavlovian Conditioned Approach Training in Rats
06:57

Pavlovian Conditioned Approach Training in Rats

Published on: February 4, 2016

10.9K

Area of Science:

  • Health Economics
  • Pharmaceutical Pricing
  • Health Policy

Background:

  • Valuing combination therapies presents challenges due to competition law, differential pricing, and component value attribution.
  • Existing methods struggle to equitably price individual components within a combination therapy.

Purpose of the Study:

  • To propose a novel value attribution solution for combination therapies.
  • To enable equitable pricing of all combination components based on their relative contribution.

Main Methods:

  • Developed a universal, symmetrical, and neutral value attribution solution.
  • Ensured the solution completely attributes combination value among components.
  • Applied the method to combinations of any size and compared it with existing approaches.

Main Results:

  • The proposed solution's outcomes fall between those of two other methods, integrating elements of each.
  • The value attribution ratios adjust with changes in additivity, reflecting incremental value impacts.

Conclusions:

  • The proposed solution offers universal applicability and component neutrality for combination therapy valuation.
  • Further research is needed to address implementation challenges, including partial information and assumption relaxation.